Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cephalon Adds Warning On Life-Threatening Skin Reaction To Provigil

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA requests updated labeling recommending the wakefulness drug be discontinued if a rash or hypersensitivity reaction occurs.

You may also be interested in...



FDA Approves Cephalon’s Nuvigil With Bolded Warning For Rash

Company tells “The Pink Sheet” DAILY it is set to begin studies in other therapeutic areas to boost labeling before commercial launch.

Nuvigil May Be Further Delayed As FDA Reviews Side Effect Profile

Cephalon plans to submit information to FDA within “the next few weeks.”

Sarepta Files DMD Gene Therapy, Seeking An Accelerated Path To Market

The company is seeking FDA accelerated approval of the closely watched gene therapy based on a surrogate marker and has proposed its fully enrolled Phase III trial to serve as a confirmatory study.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel